Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study

AstraZeneca

Status: Completed

Conditions: Bipolar Episodes; Schizophrenia

Study type: Observational

Funder types: Industry

Identifiers

NCT01689389

NIS-NFR-SER-2012/1

Details and patient eligibility

About

The aim of the study is to describe patient characteristics (demographic and clinical) and the patterns of use of Quetiapine XR in patients receiving the drug for the first time in real-life practice regardless the final diagnosis.

Full description

Description of the use of Quetiapine Extended Release (XR) in real-life practice in France

Enrollment: 2,292 patients

Sex: All

Ages: 18 to 130 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• New patients treated with Xeroquel XR
• Patients aged 18 years and over
• Diagnosis of bipolar disorder or schizophrenia according to DSM-IV criteria

Exclusion criteria

• Patient included in a therapeutic trial (Huriet-Serusclat Act)
• Patient refusing to participate in the study
• Pregnant women

Trial design

2,292 participants in 3 patient groups

Main study population

Description:

All eligible patients receiving Quetiapine XR for the first time in the inclusion period regardless the diagnosed disease or the patients' age. Patients aged 18 years and over and diagnosed with bipolar disorder or schizophrenia according to DSM-IV criteria will be followed during 12 months.

Schizophrenia SoC sample

Description:

Patients would have to be prescribed for the first time with a new (not used during the preceding 3 months) atypical antipsychotic other than Quetiapine XR (irrespective this new atypical antipsychotic is preceded or not by another atypical antipsychotic).

Bipolar SoC sample

Description:

Patients would have to be prescribed a new (not used during the preceding 3 months) antidepressant [N06A], antipsychotic (other than Quetiapine XR) [N05A] or mood stabilizer (including lithium [N05AN], valproate [N03AG01], and lamotrigine [N03AX09].